Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr tells Proactive the Philadelphia, Pennsylvania-based female-focused oncology company's four ongoing clinical trials are on track to report initial data in 2022.
Lehr says the company, which recently began trading its shares on the Nasdaq and subsequently raised more than $28 million, is well positioned to execute on its clinical milestones.